Archimedes, Inc. and FDA Announce Collaboration to Evaluate the Clinical Risks and Benefits of Weight Loss Medications

Clinical Trial Simulation Will Model Obesity Interventions
San Francisco, CA - January 20, 2011 - Archimedes Inc., a healthcare modeling company, announced today that it has entered into a Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA) to develop a computer model of clinical trials evaluating weight loss medications. The model will be used to obtain a better understanding of the benefits of weight loss against the long-term risks of cardiovascular outcomes in patients treated with weight loss drugs.

The computer model will attempt to reproduce the results of the Sibutramine Cardiovascular Outcome Trial (SCOUT), which showed that patients receiving sibutramine were 16 percent more likely to suffer serious cardiac events than those who received a placebo. The model is expected to provide insight into the relationship between patient outcomes and cardiovascular risk factors such as blood pressure, heart rate and cholesterol. The model will then be used to explore outcomes over a 10-year simulated extension of the SCOUT trial.

"We are excited about the collaborative work we are conducting with the FDA to further understand the effects of weight loss medications in a population of 'virtual' patients," said David Eddy, M.D., Ph.D, founder of Archimedes, Inc.

Archimedes will build and validate the clinical trial model using published data from the SCOUT trial and patient information from the National Health and Nutrition Examination Survey (NHANES), a widely known and validated program of studies designed to assess the health and nutritional status of adults and children in the United States. The model will also include information about physiological pathways and disease symptoms in the targeted patient populations.

About Archimedes:
Archimedes Inc. is an independent healthcare modeling organization. Its proprietary technology - the Archimedes Model - is a carefully validated and calibrated mathematical model of human physiology, diseases, interventions and healthcare systems.

The Archimedes Model is designed to help people understand the implications of their decisions and for the last 15 years has been relied upon to answer complex, real world questions for health plans, pharmaceutical companies, researchers, and other organizations. Archimedes, a Kaiser Permanente Innovation, is based in San Francisco, California. For more information on the company, visit our website at